Tyrosine kinase inhibitors were well-tolerated among patients with different etiologies of advanced HCC with lower survival in non-viral patients.
Barakat EMF, Kohla M, Dabees H, Shousha HI, Moustafa EF, El-Kassas M, Aziz MS, Elkhateeb E, Abdelaziz AO, Abdelmalek MO, Azmy A, Tawheed A, Aboganob WM, Taha H, Lithy R, Radwan A, Ghoraba D, Sayed H, Nassief A, Elhelbawy M, Nabeel MM, Medhat MA, Askar SR, Marwan E, Rewisha E, Elbaz T, Ahmed SH, Elfouly NF, Abdeen N, Abdelmaksoud AH, Abdeltawab AA, Shamkh MAA, Ramadan A, Abdelrazek YA, Bassam M, Sayed SA, Hussein RS, Alrajhi A, Allam AE, Seyam OA, Said M.
Barakat EMF, et al. Among authors: shousha hi.
Sci Rep. 2025 Jun 27;15(1):20323. doi: 10.1038/s41598-025-05828-x.
Sci Rep. 2025.
PMID: 40579411
Free PMC article.